Table 2 Clinical trials of OVs in combination with immunotherapy
Combination strategy | OV type | OV mutant | Combination agent | Targeted cancer | Trial phase | Trial status | Trial No. |
|---|---|---|---|---|---|---|---|
Immunotherapy | HSV-1 | T-Vec | Pembrolizumab (anti-PD1) | Melanoma | II, III | Active (not recruiting) | NCT02263508, NCT02965716 |
Pembrolizumab | Head and neck cancer | I | Active (not recruiting) | NCT02626000 | |||
Ipilimumab (anti-CTLA4) | Sarcoma | II | Recruiting | NCT03069378 | |||
Ipilimumab | Melanoma | I/II | Active (not recruiting) | NCT01740297 | |||
Ipilimumab +  Nivolumab (anti-PD1) | Breast cancer | I | Recruiting | NCT04185311 | |||
Atezolizumab (anti-PD-L1) | Breast cancer, colorectal cancer | I | Recruiting | NCT03256344, NCT03802604 | |||
HF10 | Ipilimumab | Melanoma | II | Completed | NCT02272855 | ||
Nivolumab | Melanoma | II | Active (not recruiting) | NCT03259425 | |||
Adenovirus | LOAd703 | Atezolizumab | Melanoma | I/II | Recruiting | NCT04123470 | |
VCN-01 | Durvalumab (anti-PD-L1) | Head and neck cancer | I | Recruiting | NCT03799744 | ||
Telomelysin | Pembrolizumab | Advanced solid tumors | I | Recruiting | NCT03172819 | ||
ONCOS-102 | Durvalumab | Peritoneal malignancies | I/II | Recruiting | NCT02963831 | ||
Reovirus | Reolysin® | Pembrolizumab | Pancreatic cancer | II | Active (not recruiting) | NCT03723915 | |
Nivolumab | Multiple myeloma | I | Recruiting | NCT03605719 | |||
Vaccinia virus Vaccinia virus | Pexa-Vec Pexa-Vec | Ipilimumab | Advanced solid tumors | I | Recruiting | NCT02977156 | |
Immunotherapy | Durvalumab +  Tremelimumab (anti-PD-L1) | Colorectal cancer | I/II | Recruiting | NCT03206073 | ||
Nivolumab | Hepatocellular carcinoma | I/II | Active (not recruiting) | NCT03071094 | |||
Coxsackie virus | CAVATAK | Pembrolizumab | Melanoma | I | Completed | NCT02565992 | |
Pembrolizumab | Non-small cell lung carcinoma, bladder cancer | I | Completed | NCT02043665 | |||
Ipilimumab | Melanoma | I | Completed | NCT02307149, NCT03408587 | |||
Pembrolizumab | Non-small cell lung carcinoma | I | Active (not recruiting) | NCT02824965 | |||
Multi-therapy | Adenovirus | LOAd703 | Atezolizumab +  Gemcitabine +  Nab-paclitaxel | Pancreatic cancer | I/II | Recruiting | NCT02705196 |
ONCOS-102 | Pembrolizumab + Cyclophosphamide | Melanoma | I | Active (not recruiting) | NCT03003676 | ||
Reovirus | Reolysin® | Pembrolizumab + Gemcitabine + FOLFIRI | Pancreatic cancer | I | Completed | NCT02620423 |